Anticuerpo anticitrulina y manifestaciones extra articulares en artritis reumatoidea

Los pacientes con artritis reumatidea (AR) pueden desarrollar manifestaciones extra articulares (MExA), relacionadas a su morbi-mortalidad. Los anticuerpos anti-peptidos citrulinados ciclicos (ACCP) son especificos para la AR y estan relacionados con el dano articular; y podrian tener rol patogenico en las MExA. Nuestro objetivo fue determinar la relacion entre los anticuerpos ACCP y MExA en pacientes con AR. Se incluyeron 74 pacientes con diagnostico de AR (ACR 1987) mayores de 18 anos, de mas de 6 meses de evolucion, con MExA, y un control apareado por sexo y edad sin MExA por cada paciente. Las variables demograficas, clinicas y de laboratorio se compararon con test t, chi cuadrado o Mann-Whitney. Se realizo analisis multivariado; p ≤ 0.05. Los pacientes con MExA presentaron mayor titulo de anticuerpo ACCP (116 vs. 34, p A large proportion of rheumatoid arthritis (RA) patients develop extra-articular manifestations (EAM), which are associated with morbidity and early mortality. Anti cyclic citrullinated peptide (ACCP) antibody has proven to be highly specific for the diagnosis of RA, associated with severe joint damage and may have some role in the pathogenesis of EAM. The aim of this study was to determine the relationship between ACCP antibody and the presence of EAM in RA patients. Seventy four RA patients (ACR 1987) with EAM, > 18 years, more than 6 months duration were included, and an EAM free control, matched by sex and age, for each patient. Demographic, clinical and laboratory variables were compared using t-test, chi-square or Mann-Whitney test. Multivariate analysis was performed: p ≤ 0.05. Patients with EAM presented a greater value of ACCP antibody (116 vs. 34, p